SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Azenta, Inc. – ‘8-K’ for 8/8/22

On:  Tuesday, 8/9/22, at 8:47pm ET   ·   As of:  8/10/22   ·   For:  8/8/22   ·   Accession #:  1558370-22-12967   ·   File #:  0-25434

Previous ‘8-K’:  ‘8-K’ on / for 8/9/22   ·   Latest ‘8-K’:  This Filing

Magnifying glass tilted right emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/10/22  Azenta, Inc.                      8-K:1,8,9   8/08/22   12:1.3M                                   Toppan Merrill Bridge/FA

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     39K 
 2: EX-2.1      Plan of Acquisition, Reorganization, Arrangement,   HTML    922K 
                Liquidation or Succession                                        
 3: EX-99.1     Miscellaneous Exhibit                               HTML     18K 
 7: R1          Document and Entity Information                     HTML     46K 
10: XML         IDEA XML File -- Filing Summary                      XML     12K 
 8: XML         XBRL Instance -- azta-20220808x8k_htm                XML     16K 
 9: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 5: EX-101.LAB  XBRL Labels -- azta-20220808_lab                     XML     45K 
 6: EX-101.PRE  XBRL Presentations -- azta-20220808_pre              XML     31K 
 4: EX-101.SCH  XBRL Schema -- azta-20220808                         XSD     13K 
11: JSON        XBRL Instance as JSON Data -- MetaLinks               11±    17K 
12: ZIP         XBRL Zipped Folder -- 0001558370-22-012967-xbrl      Zip    128K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:   C:   C:   C:   C: 
  brks_20190618_8K  
 i 0000933974 i false00009339742022-08-082022-08-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM  i 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 or 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):  i August 8, 2022

 i Azenta, Inc.

(Exact name of registrant as specified in its charter)

 i Delaware

    

 i 0-25434

    

 i 04-3040660

(State or Other Jurisdiction
of Incorporation)

 

(Commission File
Number)

 

(IRS Employer
Identification No.)

 i 15 Elizabeth Drive,  i Chelmsford,  i MA  i 01824

(Address of principal executive offices and Zip Code)

( i 978)  i 262-2400

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 i     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 i     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 i     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 i     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

    

Trading Symbol(s)

    

Name of each exchange on which registered

 i Common Stock, $0.01 par value

 i AZTA

 i The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   i 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Item 1.01. Entry into a Material Definitive Agreement.

On August 8, 2022, Azenta, Inc. (“Azenta”), and its wholly-owned subsidiary, Azenta Luxembourg S.á r.l. (“Azenta Luxembourg”), entered into a Share Purchase Agreement (the “Agreement”) with B Medical Systems Holding S.A. (the “Seller”), pursuant to which Azenta Luxembourg has agreed to acquire and the Seller has agreed to sell, all of the issued and outstanding capital shares of B Medical Systems S.á r.l. (“B Medical”). B Medical is a leading global provider of temperature-controlled storage and transportation solutions.

The total purchase price to be paid by Azenta Luxembourg is approximately €410,000,000, plus up to an additional €50,000,000 in contingent consideration that may be earned based upon achievement of certain financial metrics by B Medical and its subsidiaries following the closing. The consummation of the transaction contemplated by the Agreement is subject to customary closing conditions and is expected to occur in October 2022.

The Agreement also includes customary representations, warranties, and covenants of the parties. The representations and warranties made by each party were made solely for the benefit of the other party and (i) were not intended to be treated as categorical statements of fact, but rather as a way of allocating the risk between the parties to the Agreement if those statements prove to be inaccurate; (ii) may have been qualified in the Agreement by disclosures that were made to the other party in disclosure schedules to the Agreement; (iii) may apply contract standards of “materiality” that are different from “materiality” under the applicable securities laws; and (iv) were made only as of the date of the Agreement or such other date or dates as may be specified in the Agreement.

The foregoing description of the Agreement and the transactions contemplated thereby does not purport to be complete and is subject to, and qualified in its entirety by reference to, the Agreement. A copy of the Agreement is attached as Exhibit 2.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 8.01. Other Events.

On August 8, 2022, Azenta issued a press release announcing entry into the Agreement, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit Number

Description

2.1*+

Share Purchase Agreement, dated as of August 8, 2022, by and among Azenta, Inc., Azenta Luxembourg S.á r.l. and B Medical Systems Holding S.A.

99.1

Press Release dated August 8, 2022, issued by Azenta, Inc.

104

Cover Page Interactive Data File (embedded within the iXBRL (Inline eXtensible Business Reporting Language) document).

*

Certain schedules and exhibits have been omitted from this Exhibit pursuant to Item 601(a)(5) of Regulation S-K. Azenta, Inc. will furnish a copy of any omitted schedule or exhibit to the U.S. Securities and Exchange Commission or its staff upon request.

+

Certain confidential portions (indicated by brackets and asterisks) have been omitted from this Exhibit.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AZENTA, INC.

/s/ Jason W. Joseph

Date: August 9, 2022

Jason W. Joseph

Senior Vice President, General Counsel and Secretary


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed as of:8/10/22None on these Dates
Filed on:8/9/22
For Period end:8/8/22
 List all Filings 
Top
Filing Submission 0001558370-22-012967   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2022 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., Sep. 26, 3:07:56.1am ET